Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically Removed
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00002523 |
Recruitment Status :
Completed
First Posted : January 27, 2003
Last Update Posted : September 2, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining radiation therapy and surgery with chemotherapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare radiation therapy alone before surgery with radiation therapy plus fluorouracil and leucovorin before surgery, with and without fluorouracil and leucovorin after surgery in patients with rectal cancer that can be surgically removed.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer | Drug: fluorouracil Drug: leucovorin calcium Procedure: conventional surgery Radiation: radiation therapy | Phase 3 |
OBJECTIVES:
- Compare the disease-free and overall survival in patients with resectable adenocarcinoma of the rectum treated with preoperative radiotherapy with or without preoperative fluorouracil (5-FU) combined with leucovorin calcium (CF) and/or postoperative 5-FU/CF.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, sex, tumor location (0-5 vs 6-10 vs 11-15 cm from anal margin), and stage (T3 vs T4). Patients are randomized to 1 of 4 treatment arms.
- Arm I: Patients undergo involved-field radiotherapy 5 days a week for 5 weeks followed 3-10 weeks later by abdominoperineal resection or anal-sparing resection according to local practice in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients undergo radiotherapy as in arm I beginning on day 1 and leucovorin calcium (CF) IV followed by fluorouracil (5-FU) IV (1 hour before radiotherapy) on days 1-5 and 29-33, followed 3-10 weeks later by resection as in arm I in the absence of disease progression or unacceptable toxicity.
- Arm III: Patients undergo radiotherapy followed 3-10 weeks later by resection as in arm I. Within 3-10 weeks after resection, patients receive CF followed by 5-FU on days 1-5. Chemotherapy continues every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
- Arm IV: Patients undergo preoperative radiotherapy with concurrent chemotherapy followed by resection as in arm II and postoperative chemotherapy as in arm III.
Patients are followed every 6 months.
PROJECTED ACCRUAL: A total of 992 patients will be accrued for this study within 4 years.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1011 participants |
Allocation: | Randomized |
Primary Purpose: | Treatment |
Official Title: | FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY |
Study Start Date : | April 1993 |
Actual Primary Completion Date : | March 2003 |
Actual Study Completion Date : | January 2016 |
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 80 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Histologically confirmed resectable adenocarcinoma of the rectum
- Any grade
- Tumor macroscopically within 15 cm of anal margin on rigid rectoscopy
- Tumor tethered or partially fixed on digital rectal exam and/or T3-4 on rectal ultrasound
- No acute or subacute bowel obstruction without colostomy diversion
- No chronic inflammatory disease of the ileum and/or colon
- No primary adenocarcinoma of the anal canal
- No distant metastasis
PATIENT CHARACTERISTICS:
Age:
- 80 and under
Performance status:
- WHO 0-1
Life expectancy:
- Not specified
Hematopoietic:
- Granulocyte count greater than 2,000/mm^3
- Platelet count greater than 130,000/mm^3
Hepatic:
- Not specified
Renal:
- Creatinine less than 1.36 mg/dL
Cardiovascular:
- No angina pectoris
Other:
- No other prior malignancy except basal cell skin cancer or carcinoma in situ of the uterine cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior biologic therapy for adenocarcinoma of the rectum
Chemotherapy
- No prior chemotherapy for adenocarcinoma of the rectum
Endocrine therapy
- No prior endocrine therapy for adenocarcinoma of the rectum
Radiotherapy
- No prior radiotherapy for adenocarcinoma of the rectum
Surgery
- No prior surgery for adenocarcinoma of the rectum
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002523
Study Chair: | Jean-Francois Bosset, MD | Hopital Jean Minjoz |
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | European Organisation for Research and Treatment of Cancer - EORTC |
ClinicalTrials.gov Identifier: | NCT00002523 |
Other Study ID Numbers: |
EORTC-22921 EORTC-22921 |
First Posted: | January 27, 2003 Key Record Dates |
Last Update Posted: | September 2, 2016 |
Last Verified: | September 2016 |
stage II rectal cancer stage III rectal cancer adenocarcinoma of the rectum |
Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases Leucovorin Fluorouracil Calcium |
Levoleucovorin Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Antidotes Protective Agents Vitamin B Complex Vitamins Micronutrients |